论文部分内容阅读
近二年来我们用改良的Габризлян紫外吸收法测定了237例肺部疾病患者静脉血浆中分子含量,单位用u/dl表示。男性170例,女性67例,年龄25～96岁,31例健康人。肺炎(大叶性、节段性或间质性)患者平均中分子量(M±SD)为209±40(n=24),原发性肺癌为207±33(n=20)、喘息性支气管炎为203±36(n=26),各组与健康人224±27(n=31)比较均无显著差别(P>0.05)。支气管哮喘发作期患者为305±36(n=30),较健康人及喘息性支气管炎均有显著升高(P<0.01),缓解期患者为208±60(n=7),与健康人及喘息性支气管炎比无显著差别(P>0.05)。表明支气管哮喘的发作与血浆中分子含量增高有密切的关系,并且它的测定可以作为鉴别支气管哮喘与喘息性支气管炎的辅助指标。
In the past two years, we used modified Габризлян UV absorbance method to determine the molecular contents of venous plasma in 237 patients with pulmonary diseases. The unit is expressed in u / dl. 170 males and 67 females, aged 25 to 96 years, 31 healthy people. The mean median molecular weight (M ± SD) was 209 ± 40 (n = 24) in patients with pneumonia (lobar, segmental or interstitial), 207 ± 33 (n = 20) in primary lung cancer, asthmatic bronchus Inflammation was 203 ± 36 (n = 26). There was no significant difference between 224 ± 27 (n = 31) and normal controls (P> 0.05). The number of patients with bronchial asthma exacerbation was 305 ± 36 (n = 30), significantly higher than that of healthy people and asthmatic bronchitis (P <0.01) and 208 ± 60 (n = 7) And asthmatic bronchitis no significant difference (P> 0.05). It indicates that the onset of bronchial asthma is closely related to the increase of molecular level in plasma, and its determination can be used as an auxiliary index to distinguish bronchial asthma from asthmatic bronchitis.